

Supplementary material 1: Information sources

For commercial sponsors, we considered:

- 1/ Clinical Study Data Request (CSDR),
- 2/ the Yale University Open Data Access Project (YODA),
- 3/ the Supporting Open Access for Researchers initiative (SOAR),
- 4/ ViVli.

For non-commercial sponsor, we considered:

- 1/ the National Institute of Mental Health, National Database for Clinical Trials Related to Mental Illness (NIMH NDCT),
- 2/ The National Institute of Health, Biologic Specimen and Data Repositories Information Coordinating Center (NIH BioLINCC),
- 3/ B2Share,
- 4/ Dryad,
- 5/ the Data Repository for University of Minnesota (Drum),
- 6/ EASY,
- 7/ Edinburgh DataShare,
- 8/ FigShare,
- 9/ the Inter-university Consortium for Political and Social Research (ICPSR),
- 10/ the Swedish National data Service (SND),
- 11/ the University Medical Hospital Information Network (UMIN),
- 12/ Zenodo,
- 13/ the Early Breast Cancer Trialists' Collaborative Group (EBCTG),
- 14/ FreeBird,
- 15/ Traumatic Brain Injury – International Mission for Prognosis and Analysis of Clinical trials in TBI (TBI-IMPACT),
- 16/ Melanoma Molecular Map Project (MMMP),
- 17/ National institute of Diabetes and Digestive and Kidney Diseases (NIDDK),
- 18/ Immune Tolerance Network TrialShare (ITN Trialshare),
- 19/ Child Abuse,
- 20/ Pooled Resource Open Access Clinical trials database (ProAct).

For the different funders:

- 1/ National Institute of Health (NIH US),
- 2/ European Commission (EC Europe),
- 3/ Medical Research Council (MRC UK),
- 3/ Le programme hospitalier de recherche clinique (DGOS France),
- 4/ L'Agence nationale de la recherche (ANR France),
- 5/ Department of Defense (US DoD),
- 6/ Wellcome Trust UK,

- 7/ Canadian Institutes of Health Research (CIHR Canada),
- 8/ National Health and Medical Research Council (NHMRC Australia),
- 9/ Deutsche Forschungsgemeinschaft (DFG Germany),
- 10/ National Natural Science Foundation of China (NSFC China),
- 11/ National Institute of Health Research (NIHR UK),
- 12/ Gates Foundation US.

Supplementary material 2: Literature searches

The initial algorithm for the literature search, detailed in the registered protocol (osf.io/pb8cj), was updated on October 29th 2018 to include broader search terms.

Name of Database	Host, search interface	Initial search Search date 2018-10-29		Update search Search date 2020-09-11 Publication year 2018-2020	
		Update status of the database	Results	Update status of the database	Results Publication year From 2018-2020
Medline	Wolters Kluwer / Ovid	1946 to October Week 3 2018	548	1946 to September Week 1 2020	187
Medline daily update		October 25, 2018		September 09, 2020	
MEDLINE In-Process & Other Non-Indexed Citations		145	1946 to September 09, 2020	128	
MEDLINE Epub Ahead of Print			September 09, 2020		
Cochrane Library: Cochrane Reviews	Wiley	Issue 10 of 12, October 2018	19	Issue 9 of 12, September 2020	12
Cochrane Protocols			1		0
Cochrane Central Register of Controlled Trials		Issue 9 of 12, September 2018	416	Issue 9 of 12, September 2020	268
Science Citation Index	Clarivate Analytics / Web of Science	1945–present (2018-10-26)	862	2018–present (2020-09-10)	419
Social Science Citation Index		1956–present (2018-10-26)			

Total with duplicates		1991		1014
Total without duplicates		1544		763
New citations 2018-2020 without overlap from initial search				597
Total without overlap initial search and update search (see PRISMA flow diagram)	2141 (1544 + 597)			

MEDLINE Databases: Host: Wolters Kluwer, search interface: Ovid

1. Indexed MEDLINE-citations:

Search Strategy:

#	Searches	Results Initial search	Results Update search	Annotations
		Search date: 2018-10-29: MEDLINE 1946 to October Week 3 2018, MEDLINE Daily Update October 25, 2018	Search date: 2020-09-11: MEDLINE 1946 to September Week 1 2020, MEDLINE (Daily Update September 09, 2020.	
1	exp Access to Information/	6845	7597	Concept data sharing: MeSH terms
2	Information Dissemination/	14697	16894	
3	exp *"Information Storage and Retrieval"/	52187	58658	
4	data collection/	87165	89553	
5	datasets as topic/	2259	4417	
6	or/1-5	157717	170739	
7	exp clinical trial/	809623	868410	Concept clinical trials:

8	exp clinical trial as topic/	318580	345552	MeSH terms or textwords
9	(randomi#ed or randomly or randomi#ation or ((random* or clinical) adj3 trial*)).ti,ab,kf.	879338	997736	
10	Meta-Analysis as Topic/	16485	18279	Concept Meta-analysis: MeSH
11	meta-analysis/	93492	119228	
12	or/7-11	1489253	1650537	Concept Clinical Trials OR Meta-analysis
13	6 and 12	10206	11264	Combination of concepts: data sharing (MeSH only) AND (clinical trials OR meta-analysis)
14	(data adj6 (share* or sharing* or reuse* or reuse* or reusing or re-using)).ti,ab,kf.	7822	9921	Concept data sharing: Textwords
15	13 and 14	325	422	data sharing (MeSH terms) AND data sharing (textwords) AND (clinical trials OR meta-analysis): 1. interim result
16	((individual* or patient* or participant*) adj6 data adj6 (share* or sharing* or reuse* or reuse* or reusing or re-using)).ti,ab,kf.	756	993	Concept sharing IPD (textwords)
17	(IPD adj6 (share* or sharing* or reuse* or reuse* or reusing or re-using)).ti,ab,kf.	23	38	
18	or/16-17	772	1017	
19	12 and 18	129	179	(Clinical trials OR meta-analysis) AND textwords for sharing IPD: 2. interim result
20	(data adj1 (share* or sharing* or reuse* or reuse* or reusing or re-using)).ti,ab,kf.	3196	4262	Concept data sharing textwords

21	12 and 20	393	539	(Clinical trials OR meta-analysis) AND textwords data sharing: 3. interim result
22	15 or 19 or 21	557	738	OR-combination of interim results
23	exp animals/ not humans/	4508403	4732433	Exclusion of animals only
24	22 not 23	552	732	
25	limit 24 to (english or french or german or spanish)	548	725	Restriction to English, German, French, Spanish: Final result for indexed Medline citations
			187	Update search: limit 25 to yr="2018 - 2020"

Term/ = MeSH (Medical subject heading)

Exp term/ = exploded Mesh (incl. narrower terms)

*Exp *term/* = MeSH as major topic incl. narrower terms as major topic

Wildcards, Truncation:

= replaces exact one character

* = zero or any number of characters

adjn = terms within *n* words in any order

ti,ab,kf = textword search in title, abstract, keyword heading word (author keywords)

2. Non-Indexed MEDLINE-citations:

#	Searches	Results Initial search Search date: 2018-10-29: MEDLINE In-Process & Other Non-Indexed	Results Update search Search date: 2020-09-11: MEDLINE Epub Ahead of Print September 09, 2020, MEDLINE	Annotations

		Citations October 25, 2018, MEDLINE Epub Ahead of Print October 25, 2018	In-Process & Other Non-Indexed Citations 1946 to September 09, 2020	
1	((individual* or patient* or participant*) adj6 data adj6 (share* or sharing* or reuse* or re-use* or reusing or re-using)).ti,ab,kf.	215	323	Concept data sharing
2	(IPD adj6 (share* or sharing* or reuse* or re-use* or reusing or re-using)).ti,ab,kf.	3	7	
3	(data adj1 (share* or sharing* or reuse* or re-use* or reusing or re-using)).ti,ab,kf.	1122	1564	
4	or/1-3	1230	1727	
5	exp clinical trial/	401	521	Concept clinical trials
6	(randomi#ed or randomly or randomi#ation or ((random* or clinical) adj3 trial*)).ti,ab,kf.	138560	174420	Concept meta-analysis
7	meta-analysis as topic/	1	0	
8	meta-analysis/	34	99	
9	(meta-analy* or metaanaly*).ti,ab,kf.	27362	37834	Concept clinical trials OR meta-analysis
10	or/5-9	156727	199473	
11	4 and 10	146	191	Concepts Data sharing AND (clinical trials OR meta-analysis)
12	limit 11 to (english or french or german or spanish)	145	191	Restriction to English, French, German, Spanish: Final result for non-indexed Medline citations
			128	Update search: limit 12 to yr="2018 - 2020"

Term/ = MeSH (Medical subject heading)

Exp term/ = exploded Mesh (incl. narrower terms)

Wildcards, Truncation:

= replaces exact one character

* = zero or any number of characters

adjn = terms within *n* words in any order
 ti,ab,kf = textword search in title, abstract, keyword heading word (author keywords)

Cochrane Library (Wiley):

- Cochrane Database of Systematic Reviews
- Cochrane Protocols
- Cochrane Central Register of Controlled Trials

ID	Search	Annotations
#1	((data near share*) or (data near sharing*)):ti,ab,kw	Concept data sharing: Textword search in title, abstract, keywords
#2	(data next share*) or (data next sharing*)	Concept data sharing: Textword search in fulltext
#3	#1 or #2	Concept data sharing. 1. Interim result
#4	((patient* or participant*) near individual*):ti,ab,kw	Concept Individual patient data sharing. 2. Interim result
#5	data:ti,ab,kw	
#6	(share* or sharing*):ti,ab,kw	
#7	#4 and #5 and #6	
#8	(IPD near (share* or sharing*)):ti,ab,kw	Concept IPD sharing: 3. Interim result
#9	#3 or #7 or #8 in Cochrane Reviews, Cochrane Protocols, Trials	OR-combination of interim results. Limit to Cochrane Reviews, Protocols, Trials: final result

Results	Initial search Search date 2018-10-29	Update search Publication Year 2018-2020 Search date 2020-09-11
Cochrane Reviews	19 Issue 10 of 12, October 2018	12 Issue 9 of 12, September 2020
Cochrane Protocols	1 Issue 10 of 12, October 2018	0 Issue 9 of 12, September 2020
Trials	416 Issue 9 of 12, September 2018	268 Issue 9 of 12, September 2020

ti,ab,kw = title,abstract keywords

near = terms in any order (default: within 6 words)
 next = phrase searching: terms next to each other in the given order
 * = truncation

Via Web of Science (Clarivate Analytics):

Databases:

- **Science Citation Index Expanded (SCI-EXPANDED)**: 1945-present

- **Social Sciences Citation Index (SSCI)**: 1956-present

Set	Query	Results Initial search Search date: 2018-10-29 Time span: all years Data last updated: 2018-10-26	Results update search Search date: 2020-09-11 Timespan=2018-2020 Data last updated: 2020-09-10	Annotations
# 1	ts=("data" near/3 share*) or ("data" near/3 sharing*)	12,398	5,227	Concept data sharing
# 2	ts=((patient* or participant*) near/3 individual*)	73,929	17,281	Concept Individual patient data sharing
# 3	ts="data"	5,101,598	1,087,419	
# 4	ts=(share* or sharing*)	456,989	114,300	
# 5	#4 AND #3 AND #2	714	336	
# 6	ts=("IPD" near/6 (share* or sharing*))	23	24	Concept IPD sharing
# 7	#6 OR #5 OR #1	12,970	5,478	OR-combination of concepts
# 8	ts=(randomi?ed or "randomly" or randomi?ation)	1,044,391	201,056	Concept clinical trials
# 9	ts=((random* or "clinical") near/3 trial*)	773,198	154,885	
# 10	ts=("meta analy*" or metaanaly*)	313,038	105,276	Concept meta-analysis
# 11	#10 or #9 OR #8	1,478,458	323,705	Concept clinical trials OR meta-analysis
# 12	#11 AND #7	1,022	453	Concepts Data sharing AND (clinical trials OR meta-analysis)
# 13	#11 AND #7 Refined by: DOCUMENT TYPES: (ARTICLE OR REVIEW)	862	419	Restriction to Article or Review: final result

ts = topic: Title, Abstract, Author Keywords, Keywords Plus®

near/n = terms in any order within n words

* = truncation

? = wildcard for exact 1 character

Supplementary material 3: Study characteristics

Author	Year	Country	Type of research	Detail if type of research=other	Type of shared material
Tudur-Smith C et al.	2014	UK	Survey		IPD
Murugiah K et al.	2016	US	Survey		IPD
Krleža-Jerić K et al.	2009	Canada	Survey		IPD
Jones CW et al.	2016	US	Survey		IPD
Mayo-Wilson E et al.	2015	US	Other	Case study	IPD
Reidpath DD et al.	2001	Australia	Experim.		IPD
Chalmers I et al.	2013	UK	Other	Case study	IPD
Bergeris A et al.	2018	US	Survey		IPD
Tudur Smith C et al.	2017	UK	Other	Case study	Broader
Vaduganathan M et al.	2018	US	Metrics		IPD
Merson L et al.	2015	Vietnam	Qualitative		IPD
Rowhani-Farid A et al.	2016	Australia	Survey		IPD
Rathi V et al.	2012	US	Survey		IPD
Ali J et al.	2015	US	Survey		IPD
Hopkins C et al.	2016	UK	Survey		IPD
Sydes M et al.	2015	UK	Metrics	Case study	IPD
Polanin J et al.	2019	US	Experim.		IPD
Villain B et al.	2015	France	Survey		IPD
Asare A et al.	2016	US	Metrics		IPD
Strom B et al.	2016	US	Other	Metrics + survey	IPD
Mello M et al.	2005	US	Survey		IPD
Rathi V et al.	2014	US	Survey		IPD
Huser V et al.	2018	US	Metrics		IPD
Chapman S et al.	2014	UK	Survey		IPD
Griswold M et al.	2013	US	Survey		Broader

Cheah PY et al.	2015	Thailand	Qualitative		IPD
Hee SW et al.	2016	UK	Other	Case study	IPD
Geifman N et al.	2015	US	Metrics		IPD
Strom B et al.	2014	US	Metrics		IPD
Ross J et al.	2016	US	Survey		IPD
Boutron I et al.	2016	France	Survey		Broader
Vidal-Infer A et al.	2018	Spain	Survey		Broader
Krumholz H et al.	2016	US	Metrics		IPD
Tannenbaum S et al.	2018	US	Survey		IPD
Ross J et al.	2017	US	Metrics		IPD
Mello M et al.	2018	US	Survey		IPD
Chickramane A et al.	2017	India	Survey		IPD
Howe N et al.	2018	UK	Qualitative		IPD
Naudet F et al.	2018	US	Survey		IPD
Yuanyuan J et al.	2017	China	Survey		IPD
Spence O et al.	2018	US	Survey		IPD
Polanin J et al.	2018	US	Survey		IPD
Zhu C et al.	2017	US	Metrics		IPD
So D et al.	2017	Canada	Survey		IPD
Savage C et al.	2009	US	Survey		IPD
Kawahara T et al.	2018	Japan	Metrics		IPD
Goldacre B et al.	2017	UK	Survey		IPD
Pisani E et al.	2017	UK	Other	Metrics + Qualitative research	IPD
Bertagnolli M et al.	2017	US	Metrics		IPD
Coady S et al.	2017	US	Metrics		IPD
Hopkins A et al.	2018	Australia	Survey	Survey	IPD
Piwowar H et al.	2007	US	Survey		IPD
Laine C et al.	2009	US	Survey		Broader
Shmueli-Blumberg D et al.	2013	US	Metrics		IPD
de Vito N et al.	2018	UK	Survey		Broader

Nevitt S et al.	2017	UK	Survey	IPD
Ahmed I et al.	2011	UK	Survey	IPD
Navar A et al.	2016	USA	Metrics	IPD
Ebrahim S et al.	2014	USA	Survey	IPD
Vassar M et al.	2020	USA	Survey	IPD
Cheah PY et al.	2018	Thailand	Qualitative	IPD
Staham EE et al.	2020	USA	Survey	Broader
Nutu D et al.	2019	Romania	Survey	IPD
Aleixandre-Benavent R et al.	2019	Spain	Survey	IPD
Ross JS et al.	2018	USA	Metrics	Broader
Gorman DM et al.	2019	USA	Survey	IPD
Bosserdt M et al.	2019	Germany	Survey	IPD
Whitlock EP et al.	2019	USA	Survey	IPD
Gabelica M et al.	2019	Croatia	Survey	IPD
Gorman DM et al.	2020	USA	Survey	IPD
Kaufmann I et al.	2019	UK	Survey	IPD
Veroniki AA et al.	2019	Greece	Experim.	IPD
Godolphin PJ et al.	2019	UK	Experim.	Broader
Rowhani-Farid A et al.	2020	USA	Experim.	IPD
Siebert M et al.	2020	France	Survey	IPD
Mayer C et al.	2019	USA	Survey	IPD
Gaba JF et al.	2020	France	Survey	Broader
Colombo C et al.	2019	Italy	Survey	IPD
Kochhar S et al.	2019	India	Metrics	IPD
Broes S et al.	2020	Belgium	Qualitative	IPD
Rollando P et al.	2020	France	Survey	Broader
Schmidt H et al.	2018	Germany	Metrics	IPD
Azar M et al.	2020	Canada	Survey	IPD
Almaqrami BS et al.	2020	China	Survey	IPD

Papageorgiou SN et al.	2019	Switzerland	Survey	iPD
Miller J et al.	2019	USA	Survey	Broader
Lovato L et al.	2018	USA	Metrics	IPD
Kemper JM et al.	2020	Australia	Survey	IPD
Johnson AL et al.	2020	USA	Survey	Broader
Sherry C et al.	2019	USA	Survey	Broader
Pellen C et al.	2020	France	Survey	Broader
Danchev V et al.	2020	USA	Survey	IPD
Li R et al.	2020	USA	Metrics	IPD

Broader: the definition is not solely restricted to IPD and can cover other type of additional material (e.g. protocol, code, etc).

Supplementary material 4: Published studies about YODA and CSDR

Reference	Repository/ platform	No. of trials included in repository/ platform	No. of requests	No. of access to data	No. of publications	Date of assessment
Ross, 2017	YODA	189	73	50	2	6/2017
Vaduganathan, 2018	YODA	537		30	3	5/2017
Strom, 2016	CSDR	237	177	144	1*	11/2015

*based upon an investigator survey with 24 responses

Supplementary material 5: Published outputs from YODA (up to 1st July 2019) and CSDR (up to 31 August 2019)

Published outputs	Title	Platform used	Identification of the proposal	Type of study	Request date
Allott EH et al. 2017	Statin Use, Serum Lipids, and Prostate Inflammation in Men with a Negative Prostate Biopsy: Results from the REDUCE Trial.	CSDR	631	Secondary analysis	29/10/2013
Moreira DM et al. 2015	Smoking Is Associated with Acute and Chronic Prostatic Inflammation: Results from the REDUCE Study.	CSDR	631	Secondary analysis	29/10/2013
Branche BL et al. 2017	Sleep Problems are Associated with Development and Progression of Lower Urinary Tract Symptoms: Results from REDUCE.	CSDR	631	Secondary analysis	29/10/2013
Vidal AC et al. 2016	Racial differences in prostate inflammation: results from the REDUCE study.	CSDR	631	Secondary analysis	29/10/2013
Simon RM et al. 2016	Does Prostate Size Predict the Development of Incident Lower Urinary Tract Symptoms in Men with Mild to No Current Symptoms? Results from the REDUCE Trial.	CSDR	631	Secondary analysis	29/10/2013
Simon RM et al. 2017	Does Peak Urine Flow Rate Predict the Development of Incident Lower Urinary Tract Symptoms in Men with Mild to No Current Symptoms? Results from REDUCE.	CSDR	631	Secondary analysis	29/10/2013
Moreira DM et al. 2015	Chronic baseline prostate inflammation is associated with lower tumor volume in men with prostate cancer on repeat biopsy: Results from the REDUCE study.	CSDR	631	Secondary analysis	29/10/2013
Kent DM et al. 2016	Risk and treatment effect heterogeneity: re-analysis of individual participant data from 32 large clinical trials.	CSDR	647	Methodological	29/10/2013
Baay M et al. 2017	Background rates of disease in Latin American children from a rotavirus vaccine study.	CSDR	651	Secondary analysis	11/03/2014
Le Noury J et al. 2015	Restoring Study 329: efficacy and harms of paroxetine and imipramine in treatment of major depression in adolescence.	CSDR	669	Re-analysis	27/01/2014
Nevitt SJ et al. 2017	Exploring changes over time and characteristics associated with data retrieval across individual participant data meta-analyses: systematic review.	CSDR	674	Methodological	15/05/2014
Nevitt SJ et al. 2017	Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data.	CSDR	674	Meta-analysis	15/05/2014

Forbess LJ et al. 2017	Failure of a systemic lupus erythematosus response index developed from clinical trial data: lessons examined and learned.	CSDR	911	Secondary analysis	25/07/2014
Dennis JM et al. 2018	Evaluating associations between the benefits and risks of drug therapy in type 2 diabetes: a joint modeling approach.	CSDR	930	Secondary analysis	missing
Dennis JM et al. 2018	Sex and BMI Alter the Benefits and Risks of Sulfonylureas and Thiazolidinediones in Type 2 Diabetes: A Framework for Evaluating Stratification Using Routine Clinical and Individual Trial Data.	CSDR	930	Secondary analysis	missing
Serrano-Villar S et al. 2017	Effects of Maraviroc versus Efavirenz in Combination with Zidovudine-Lamivudine on the CD4/CD8 Ratio in Treatment-Naive HIV-Infected Individuals.	CSDR	945	Secondary analysis	23/04/2014
Mistry HB et al. 2017	Model based analysis of the heterogeneity in the tumour size dynamics differentiates vemurafenib, dabrafenib and trametinib in metastatic melanoma.	CSDR	946	Secondary analysis	28/05/2014
Muff S et al. 2018	Bias away from the null due to miscounted outcomes? A case study on the TORCH trial.	CSDR	977	Re-analysis	12/05/2014
Fragoso CAV et al. 2018	Spirometric Criteria for Chronic Obstructive Pulmonary Disease in Clinical Trials of Pharmacotherapy.	CSDR	993	Secondary analysis	28/02/2017
Devilliers H et al. 2016	Minimal Clinically Important Differences for Generic Patient Reported Outcomes Tools in SLE	CSDR	998	Secondary analysis	missing
Li-Kim-Moy J et al. 2018	Impact of Fever and Antipyretic Use on Influenza Vaccine Immune Responses in Children.	CSDR	1000	Secondary analysis	08/09/2014
Blanco JR et al. 2017	Impact of dolutegravir and efavirenz on immune recovery markers: results from a randomized clinical trial.	CSDR	1028	Secondary analysis	23/09/2014
Borges NA et al. 2016	Nonnucleoside Reverse-transcriptase Inhibitor- vs Ritonavir-boosted Protease Inhibitor-based Regimens for Initial Treatment of HIV Infection: A Systematic Review and Metaanalysis of Randomized Trials.	CSDR	1058	Meta-analysis	18/08/2014
Dodd S et al. 2018	Incidence and characteristics of the nocebo response from meta-analyses of the placebo arms of clinical trials of olanzapine for bipolar disorder.	CSDR	1078	Meta-analysis	09/10/2014
Serrano-Villar S et al. 2017	Effects of Maraviroc versus Efavirenz in Combination with Zidovudine-Lamivudine on the CD4/CD8 Ratio in Treatment-Naive HIV-Infected Individuals.	CSDR	1079	Secondary analysis	12/10/2014
Emamikia S et al. 2017	Relationship between glucocorticoid dose and adverse events in systemic lupus erythematosus: data from a randomized clinical trial.	CSDR	1084	Secondary analysis	20/02/2015

Gruber JF et al. 2018	Timing and predictors of severe rotavirus gastroenteritis among unvaccinated infants in low- and middle-income countries.	CSDR	1088	Secondary analysis	04/09/2015
Gruber JF et al. 2018	Timing of Rotavirus Vaccine Doses and Severe Rotavirus Gastroenteritis Among Vaccinated Infants in Low- and Middle-income Countries.	CSDR	1088	Secondary analysis	04/09/2015
Schwartz LM et al. 2016	Rotavirus vaccine effectiveness in low-income settings: An evaluation of the test-negative design.	CSDR	1090	Secondary analysis	15/04/2015
Hilkens NA et al. 2016	Blood pressure levels and the risk of intracerebral hemorrhage after ischemic stroke.	CSDR	1100	Secondary analysis	13/01/2015
Hieronimus F et al. 2017	Efficacy of selective serotonin reuptake inhibitors in the absence of side effects: a mega-analysis of citalopram and paroxetine in adult depression.	CSDR	1103	Meta-analysis	missing
Waljee AK et al. 2018	Predicting corticosteroid-free endoscopic remission with vedolizumab in ulcerative colitis.	CSDR	1136	Secondary analysis	13/08/2015
Hadjichrysanthou C et al. 2016	Understanding the within-host dynamics of influenza A virus: from theory to clinical implications.	CSDR	1137	Secondary analysis	16/04/2015
Voysey M et al. 2017	The Influence of Maternally Derived Antibody and Infant Age at Vaccination on Infant Vaccine Responses : An Individual Participant Meta-analysis.	CSDR	1141	Meta-analysis	22/07/2015
Radua J et al. 2017	Meta-Analysis of the Risk of Subsequent Mood Episodes in Bipolar Disorder.	CSDR	1148	Meta-analysis	30/01/2015
de Vries YA et al. 2018	Initial severity and antidepressant efficacy for anxiety disorders, obsessive-compulsive disorder, and posttraumatic stress disorder: An individual patient data meta-analysis.	CSDR	1173	Meta-analysis	30/06/2015
Zafack JG et al. 2019	Adverse events following immunisation with four-component meningococcal serogroup B vaccine (4CMenB): interaction with co-administration of routine infant vaccines and risk of recurrence in European randomised controlled trials.	CSDR	1224	Secondary analysis	missing
Sturm A et al. 2017	Evaluating the Hierarchical Structure of ADHD Symptoms and Invariance Across Age and Gender.	CSDR	1292	Methodological	29/07/2015
Oon S et al. 2019	Lupus Low Disease Activity State (LLDAS) discriminates responders in the BLISS-52 and BLISS-76 phase III trials of belimumab in systemic lupus erythematosus.	CSDR	1320	Secondary analysis	missing
Craig K et al. 2017	More of what works: Detection of informative sites during the conduct of clinical trials using machine learning	CSDR	1323	Methodological	21/10/2015

Bauza C et al. 2018	Determining the Joint Effect of Obesity and Diabetes on All-Cause Mortality and Cardiovascular-Related Mortality following an Ischemic Stroke.	CSDR	1331	Secondary analysis	28/01/2016
Bauza C et al. 2018	Determining the joint effect of obesity and diabetes on functional disability at 3-months and on all-cause mortality at 1-year following an ischemic stroke.	CSDR	1331	Secondary analysis	28/01/2016
Tajgardoon M et al. 2018	A Novel Representation of Vaccine Efficacy Trial Datasets for Use in Computer Simulation of Vaccination Policy.	CSDR	1374	Secondary analysis	25/05/2016
Berenguer J et al. 2019	Mathematical modeling of HIV-1 transmission risk from condomless anal intercourse in HIV-infected MSM by the type of initial ART.	CSDR	1403	Secondary analysis	missing
Hilkens NA et al. 2017	Predicting Major Bleeding in Ischemic Stroke Patients With Atrial Fibrillation.	CSDR	1455	Secondary analysis	03/06/2016
Kerr SJ et al. 2017	The FDA snapshot algorithm may overestimate the efficacy of initial art	CSDR	1456	Methodological	missing
Samara MT et al. 2017	Initial symptom severity of bipolar I disorder and the efficacy of olanzapine: a meta-analysis of individual participant data from five placebo-controlled studies.	CSDR	1457	Meta-analysis	08/06/2016
Hopkins AM et al. 2018	Risk Factors for Severe Diarrhea with an Afatinib Treatment of Non-Small Cell Lung Cancer: A Pooled Analysis of Clinical Trials.	CSDR	1475	Meta-analysis	missing
Peters EM et al. 2018	Melancholic Symptoms in Bipolar II Depression and Responsiveness to Lamotrigine in an Exploratory Pilot Study.	CSDR	1569	Secondary analysis	01/11/2016
de Vries YA et al. 2018	Predicting antidepressant response by monitoring early improvement of individual symptoms of depression: individual patient data meta-analysis.	CSDR	1575	Meta-analysis	11/10/2016
Gemeinsamer Bundesausschuss, 2019	Nutzenbewertungsverfahren zum Wirkstoff Sitagliptin	CSDR	1593	Secondary analysis	04/11/2016
Hopkins AM et al. 2019	Effect of early adverse events on response and survival outcomes of advanced melanoma patients treated with vemurafenib or vemurafenib plus cobimetinib: A pooled analysis of clinical trial data.	CSDR	1599	Meta-analysis	missing
Carbon M et al. 2018	Tardive dyskinesia risk with first- and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis.	CSDR	1624	Meta-analysis	missing

Schwarzman LS et al. 2018	The Association of Previous Prostate Biopsy Related Complications and the Type of Complication with Patient Compliance with Rebiopsy Scheme.	CSDR	1626	Secondary analysis	16/12/2016
Voysey M et al. 2017	Prevalence and decay of maternal pneumococcal and meningococcal antibodies: A meta-analysis of type-specific decay rates.	CSDR	1629	Meta-analysis	26/09/2016
Shapiro W et al. 2018	Salmeterol Combined with Fluticasone Reduces Exacerbations More Effectively in Chronic Bronchitis Associated with Chronic Obstructive Pulmonary Disease: A Post-hoc Analysis of the TORCH Trial	CSDR	1640	Secondary analysis	28/02/2017
Parodis I et al. 2018	Clinical SLEDAI-2K zero may be a pragmatic outcome measure in SLE studies.	CSDR	1695	Secondary analysis	21/09/2017
Parodis I et al. 2019	Established organ damage reduces belimumab efficacy in systemic lupus erythematosus.	CSDR	1695	Secondary analysis	21/09/2017
Parodis I et al. 2019	Predictors of low disease activity and clinical remission following belimumab treatment in systemic lupus erythematosus.	CSDR	1695	Secondary analysis	21/09/2017
Hernández-Breijo B et al. 2019	Antimalarial agents diminish while methotrexate, azathioprine and mycophenolic acid increase BAFF levels in systemic lupus erythematosus.	CSDR	1695	Secondary analysis	21/09/2017
Hopkins AM et al. 2019	Predictors of Long-Term Disease Control and Survival for HER2-Positive Advanced Breast Cancer Patients Treated With Pertuzumab, Trastuzumab, and Docetaxel.	CSDR	1741	Secondary analysis	missing
Janciauskiene S et al. 2019	Serum Levels of Alpha1-antitrypsin and Their Relationship With COPD in the General Spanish Population.	CSDR	2084	Secondary analysis	missing
Storgaard H et al. 2016	Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.	YODA	2014-0340	Meta-analysis	19/11/2014
Christian KE et al. 2019	Gender Differences and Other Factors Associated with Weight Gain Following Initiation of Infliximab: A Post Hoc Analysis of Clinical Trials.	YODA	2014-0334	Meta-analysis	26/11/2014
Wang R et al. 2018	Comparative Efficacy of Tumor Necrosis Factor- α Inhibitors in Ankylosing Spondylitis: A Systematic Review and Bayesian Network Metaanalysis.	YODA	2014-0291	Meta-analysis	08/12/2014
Waljee AK et al. 2017	External Validation of a Thiopurine Monitoring Algorithm on the SONIC Clinical Trial Dataset.	YODA	2014-0401	Secondary analysis	20/01/2015
Mospan GA et al. 2017	5-Day versus 10-Day Course of Fluoroquinolones in Outpatient Males with a Urinary Tract Infection (UTI).	YODA	2015-0514	Secondary analysis	26/05/2015

Singh S et al. 2018	Impact of Obesity on Short- and Intermediate-Term Outcomes in Inflammatory Bowel Diseases: Pooled Analysis of Placebo Arms of Infliximab Clinical Trials.	YODA	2015-0612	Meta-analysis	20/10/2015
Singh S et al. 2018	Obesity and Response to Infliximab in Patients with Inflammatory Bowel Diseases: Pooled Analysis of Individual Participant Data from Clinical Trials.	YODA	2015-0612	Meta-analysis	20/10/2015
Spertus J et al. 2018	Risk of weight gain for specific antipsychotic drugs: a meta-analysis.	YODA	2015-0678	Meta-analysis	29/01/2016
Spertus J et al. 2019	Bayesian Meta-analysis of Multiple Continuous Treatments with Individual Participant-Level Data: An Application to Antipsychotic Drugs.	YODA	2015-0678	Meta-analysis	29/01/2016
Zou X et al. 2018	The role of PANSS symptoms and adverse events in explaining the effects of paliperidone on social functioning: a causal mediation analysis approach.	YODA	2016-0716	Secondary analysis	24/02/2016
World Health Organization 2017	WHO report (appendix)	YODA	2016-0734	Meta-analysis	24/02/2016
Mbuagbaw L et al. 2019	Outcomes of Bedaquiline Treatment in Patients with Multidrug-Resistant Tuberculosis.	YODA	2016-0734	Meta-analysis	24/02/2016
Corbett M et al. 2017	Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease-modifying antirheumatic drugs: a systematic review and economic evaluation.	YODA	2016-0897	Meta-analysis	19/05/2016
Gay HC et al. 2017	Feasibility, Process, and Outcomes of Cardiovascular Clinical Trial Data Sharing: A Reproduction Analysis of the SMART-AF Trial.	YODA	2016-0912	Re-analysis	07/06/2016
Schneider-Thoma J et al. 2018	Second-generation antipsychotic drugs and short-term mortality: a systematic review and meta-analysis of placebo-controlled randomised controlled trials.	YODA	2016-0880	Meta-analysis	17/06/2016
Schneider-Thoma J et al. 2019	Second-generation antipsychotic drugs and short-term somatic serious adverse events: a systematic review and meta-analysis.	YODA	2016-0880	Meta-analysis	17/06/2016
Teply BA et al. 2019	Risk of development of visceral metastases subsequent to abiraterone vs placebo: An analysis of mode of radiographic progression in COU-AA-302.	YODA	2016-1057	Secondary analysis	01/09/2016
Loubersac T et al. 2019	Neutrophil-to-lymphocyte Ratio as a Predictive Marker of Response to Abiraterone Acetate: A Retrospective Analysis of the COU302 Study.	YODA	2016-1103	Secondary analysis	23/11/2016
Martin LJ et al. 2018	Identification of subgroups of metastatic castrate-resistant prostate cancer (mCRPC) patients treated with abiraterone	YODA	2016-1122	Secondary analysis	23/11/2016

	plus prednisone at low- vs. high-risk of radiographic progression: An analysis of COU-AA-302.				
Waljee AK et al. 2019	Development and Validation of Machine Learning Models in Prediction of Remission in Patients With Moderate to Severe Crohn Disease.	YODA	2016-1176	Secondary analysis	01/03/2017
Kubo K et al. 2018	Placebo effects in adult and adolescent patients with schizophrenia: combined analysis of nine RCTs.	YODA	2017-1676	Meta-analysis	24/05/2017
Kumagai F et al. 2018	Early Placebo Improvement Is a Marker for Subsequent Placebo Response in Long-Acting Injectable Antipsychotic Trials for Schizophrenia: Combined Analysis of 4 RCTs.	YODA	2017-1701	Meta-analysis	01/06/2017
Yiu ZZN et al. 2019	A standardization approach to compare treatment safety and effectiveness outcomes between clinical trials and real-world populations in psoriasis.	YODA	2017-1706	Methodological	08/08/2017
Narula N et al. 2018	Patient-Reported Outcomes and Endoscopic Appearance of Ulcerative Colitis: A Systematic Review and Meta-analysis.	YODA	2017-2031	Meta-analysis	30/08/2017
Singh S et al. 2018	No Benefit of Concomitant 5-Aminosalicylates in Patients With Ulcerative Colitis Escalated to Biologic Therapy: Pooled Analysis of Individual Participant Data From Clinical Trials.	YODA	2017-2306	Meta-analysis	25/09/2017
Singh S et al. 2019	Efficacy and Speed of Induction of Remission of Infliximab vs Golimumab for Patients With Ulcerative Colitis, Based on Data From Clinical Trials.	YODA	2018-3121	Meta-analysis	21/05/2018